Literature DB >> 7104186

Plasma protein binding of phenytoin in 100 epileptic patients.

G M Peterson, S McLean, S Aldous, R J Von Witt, K S Millingen.   

Abstract

The plasma protein binding of phenytoin was investigated in 100 epileptic patients, using equilibrium dialysis at 37 degrees C. The unbound fractions of phenytoin in plasma formed a skewed distribution, with a range of 9.7 to 24.7% and a median value of 12.3%. Most (80%) patients appeared to form one group with free phenytoin fractions from 9.7 to 14.5%, while the remainder formed a group with elevated free fractions (greater than 14.5%). Total and unbound plasma concentrations of phenytoin were strongly correlated (r=0.95, P less than 0.0001). There was a weak correlation between increasing age and the unbound phenytoin fraction (r=0.28, P less than 0.01). The results indicate that measurement of the total phenytoin concentration in plasma should usually provide a reliable index of anticonvulsant effect. However, determination of the unbound phenytoin fraction would be beneficial in the management of those patients in whom this fraction may be elevated, due to interacting drugs or biochemical abnormalities.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7104186      PMCID: PMC1427743          DOI: 10.1111/j.1365-2125.1982.tb01981.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.

Authors:  P K Lunde; A Rane; S J Yaffe; L Lund; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1970 Nov-Dec       Impact factor: 6.875

2.  Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication.

Authors:  H E Booker; B Darcey
Journal:  Epilepsia       Date:  1973-06       Impact factor: 5.864

3.  Diphenylhydantoin concentrations in saliva.

Authors:  F Bochner; W D Hooper; J M Sutherland; M J Eadie; J H Tyrer
Journal:  Arch Neurol       Date:  1974-07

4.  Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease.

Authors:  W D Hooper; F Bochner; M J Eadie; J H Tyrer
Journal:  Clin Pharmacol Ther       Date:  1974-03       Impact factor: 6.875

5.  Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid.

Authors:  L Lund; A Berlin; K M Lunde
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

6.  Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.

Authors:  M Ehrnebo; S Agurell; B Jalling; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1971-09       Impact factor: 2.953

7.  Diphenylhydantoin as an anticonvulsant: protein binding and fluctuation of the serum and cerebrospinal fluid levels in forty mentally subnormal epileptics.

Authors:  N M Viukari; P Tammisto
Journal:  J Ment Defic Res       Date:  1969-12

8.  Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding.

Authors:  M J Hayes; M J Langman; A H Short
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

9.  Plasma albumin concentration and diphenylhydantoin binding in man.

Authors:  R J Porter; R B Layzer
Journal:  Arch Neurol       Date:  1975-05

10.  Diphenylhydantoin, phenobarbital, and primidone in saliva, plasma, and cerebrospinal fluid.

Authors:  D Schmidt; J Kupferberg
Journal:  Epilepsia       Date:  1975-12       Impact factor: 5.864

View more
  19 in total

Review 1.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

Review 3.  Plasma protein binding of drugs in the elderly.

Authors:  S M Wallace; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

4.  Monitoring free plasma concentrations of phenytoin.

Authors:  G M Peterson; S McLean
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

5.  Effect of age and sex on the plasma binding of acidic and basic drugs.

Authors:  R K Verbeeck; J A Cardinal; S M Wallace
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Audit of a monitoring service for free phenytoin.

Authors:  G M Peterson; S McLean; R J von Witt; K S Millingen
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

7.  Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method.

Authors:  M E Veronese; S McLean; R Hendriks
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

8.  Should we routinely measure free plasma phenytoin concentration?

Authors:  E M Rimmer; D C Buss; P A Routledge; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

Review 9.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

10.  Plasma concentrations of unbound phenytoin in the management of epilepsy.

Authors:  C J Kilpatrick; S Wanwimolruk; L M Wing
Journal:  Br J Clin Pharmacol       Date:  1984-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.